HAMP and anemia (phenotype): Experiments with the PG-APS rat model of AI confirmed that momelotinib ameliorates anemia in response to hepcidin inhibition; moreover, they demonstrated that this response is caused by momelotinib-mediated targeting of ALK2 [121].